ArticleThe open rheumatology journal2011
Synovial tissue response to treatment in psoriatic arthritis.
Article in The open rheumatology journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Tumor necrosis factor (TNF) inhibitors for psoriatic arthritis.The Cochrane database of systematic reviews · 2025Pooled it
- From Bed to Bench and Back: TNF-α, IL-23/IL-17A, and JAK-Dependent Inflammation in the Pathogenesis of Psoriatic Synovitis.Frontiers in pharmacology · 2021Review
- Profile of certolizumab and its potential in the treatment of psoriatic arthritis.Drug design, development and therapy · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following its validation and wide application in rheumatoid arthritis (RA), synovial tissue analysis has recently been applied to studies on Psoriatic Arthritis (PsA). Such studies aim to thereby clarify its distinctive features and the nature of specific responses upon administration of disease modifying anti-rheumatic drug (DMARD) or biologic agents. In consequence, insights to disease pathogenesis, drugs' mechanisms of action (MOA) and biomarkers of response have emerged. Data from pilot and open-label studies, and recently from randomized controlled trials, have helped in refining the therapeutic approaches to PsA patients, by improving understanding of MOA and in provision of biomarkers of response. The availability of less invasive and reproducible analysis techniques to obtain and evaluate synovial biopsies will further enhance the utility of this approach in due course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.